NIH Center for Scientific Review Notice of Closed Meetings (April 2026)
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This Federal Register notice announces 13 closed virtual meetings of the National Institutes of Health Center for Scientific Review scheduled between April 16 and April 23, 2026. All meetings are held at the NIH Rockledge II building in Bethesda, Maryland, but conducted virtually. The meetings involve review and evaluation of grant applications in various scientific fields including neuroscience, cancer research, liver disease, eye diseases, respiratory topics, addiction prevention, population analytics, immunology, infectious diseases, and institutional training grants. The meetings are closed to the public under 5 U.S.C. 552b(c)(4) and 552b(c)(6) to protect confidential trade secrets, commercial property, patentable material, and personal privacy of applicants.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- 13 closed virtual grant review meetings scheduled April 16-23 2026
- All meetings held virtually at NIH Rockledge II, Bethesda MD
- Meetings closed to public under 5 U.S.C. 552b(c)(4) and 552b(c)(6)
+ 3 more changes with Pro
Obligations
What this law requires
Conduct 13 closed virtual meetings of the NIH Center for Scientific Review between April 16-23, 2026 at the specified dates and times for grant application review and evaluation
Close all meetings to the public in accordance with 5 U.S.C. 552b(c)(4) and 552b(c)(6) to protect confidential trade secrets, commercial property, patentable material, and personal privacy of grant applicants
Designate a specific Scientific Review Officer as the contact person for each of the 13 meetings and provide their contact information (name, phone, email) for public inquiry
Hold all meetings virtually at the NIH Rockledge II building location (6701 Rockledge Drive, Bethesda, MD 20892) as the official address
Restrict disclosure of grant applications and meeting discussions to prevent unauthorized access to confidential trade secrets, commercial property, and personal information of applicants